Ricevi le ultime notizie sulle azioni Assembly Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ASMB

Ultime notizie per

Assembly Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

ADC Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Evommune

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Inventiva S.A. - American Depository Shares

Inventiva

Invivyd

Jade Biosciences

Keros Therapeutics

Lexeo Therapeutics

MeiraGTx Hldgs

Monopar Therapeutics

MapLight Therapeutics, Inc. - Common Stock

MapLight Therapeutics

Myriad Genetics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Regenxbio

Verastem

Assembly Biosciences (ASMB) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Comments

Assembly Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO